Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Juul e-cigarettes have grown in popularity amongst teens since they are discreet, easy to use, powerful and have good flavor pods. Photo: Brianna Soukup/Portland Press Herald via Getty Images

A group of public health organizations and doctors filed a lawsuit against the Food and Drug Administration Tuesday for delaying its review of e-cigarettes — a growing concern amongst parents and pediatricians due to increased reports of adolescents and teenagers picking up "vaping" or "juuling" (when using a popular brand, Juul).

Why it matters:

"Juul is an e-cigarette that looks like a USB flash drive, charges on your computer, and is sold in sweet flavors...Each pod contains as much nicotine as a pack of cigarettes. There are widespread reports it's being used in high schools and junior high schools...It's exactly the kind of product the FDA needs to be reviewing now and taking action to protect our kids."
— Vince Willmore, spokesperson for Campaign for Tobacco-Free Kids (CTFK), tells Axios

FDA response: FDA has been examining lowering nicotine levels in regular cigarettes and is looking at limiting flavors in cigarettes and e-cigarettes. While there was no official comment on the lawsuit, FDA commissioner Scott Gottlieb sent out several messages on Twitter Tuesday that said the agency will be "out soon" with new policies:

Industry response: A Juul Labs spokesperson tells Axios: "JUUL Labs’ mission is to eliminate cigarette smoking by offering existing adult smokers a true alternative to cigarettes. JUUL is not intended for anyone else. We strongly condemn the use of our product by minors, and it is in fact illegal to sell our product to minors. No minor should be in possession of a JUUL product."

"This lawsuit is nothing more than another shameless attempt by supposed public health groups to demagogue e-cigarettes, fully knowing that FDA already has recognized e-cigarettes are a lower-risk alternative to combustible cigarettes. We have worked diligently with this administration on its approach to regulation of the e-cigarette industry and will continue to do so. We encourage these groups do to the same."
— Tony Abboud, executive director of Vapor Technology Association

Background: E-cigarettes are touted by some as a safe way for adults to quit smoking cigarettes. Wired writes a British study showed in 2017 that the practice has shown some success in helping adults quit. When vaping, the e-liquids are heated and inhaled with a reusable tool — and since it doesn't contain the tar in cigarettes, it's considered to be less carcinogenic.

Yes, but: A NAS study in January 2018 said that although they have less carcinogens, "E-cigarette smokers might have a higher risk than nonsmokers of developing lung and bladder cancers and heart diseases."

And, as pointed out by the New York Times, a growing concern is that the nicotine in e-cigarettes is creating young addicts who could eventually turn to smoking the more harmful cigarettes. A member of the American Academy of Pediatrics (AAP) Tobacco Consortium tells Axios this may be the case:

"E-cigarettes are now the most commonly used tobacco product among youth in the United States. They have dramatically expanded the total number of adolescents who use any tobacco product.”
— Harvard Medical School's Jonathan P. Winickoff, a practicing pediatrician

Details of the lawsuit, via the accompanying press release:

  • The trigger: In August 2017, the FDA delayed until 2021/2022 a key provision of a rule requiring manufacturers to provide critical product info to the FDA and undergo an FDA review of impact on public health, including whether it appeals to kids. Meanwhile, the products remain on the market.
  • The lawsuit alleges this delay "exceeds the agency’s authority" and "violates the Administrative Procedure Act because the FDA did not give the public an opportunity to comment on the change and did not articulate an adequate factual basis for this radical change from the deadlines the FDA itself established in the deeming rule."
  • The members of the lawsuit include AAP, AAP's Maryland Chapter, CTFK, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Truth Initiative and four pediatricians.

Separately, recent science studies show nicotine is not the only ingredient to worry about in e-cigarettes.

1. The University of Rochester Medical Centre led a study in Frontiers in Physiology Jan. 30 that says e-cigarettes harm white blood cells, and that certain flavoring compounds — cinnamon, vanilla and butter — are particularly harmful. They also point out mixing flavors has a much worse effect than exposure to just one.

2. The University of North Carolina published a study Tuesday in PLOS Biology that says it confirms those three flavors in e-cigarettes are more toxic to humans than others.

  • Some of the harmful effects include immunosuppression, altered mucus secretion and protein changes in the cells from the lining of the lungs, according to study author Flori Sassano.
  • "We need regulatory measures to prevent chemicals like these to be used to make e-liquids or at least limit their concentration to safe levels to avoid toxic effects," Sassono tells Axios.

Go deeper

Caitlin Owens, author of Vitals
3 hours ago - Health

Pfizer CEO feels "liberated" after taking COVID vaccine

Pfizer CEO Albert Bourla. Photo: "Axios on HBO"

Pfizer CEO Albert Bourla tells "Axios on HBO" that he recently received his first of two doses of the company's coronavirus vaccine.

Why it matters: Bourla told CNBC in December that company polling found that one of the most effective ways to increase confidence in the vaccine was to have the CEO take it.

Dan Primack, author of Pro Rata
3 hours ago - Economy & Business

Ripple CEO: SEC lawsuit is "bad for crypto" in the U.S.

Ripple CEO Brad Garlinghouse tells "Axios on HBO" that if his company loses a lawsuit brought by U.S. regulators, it would put the country at a competitive disadvantage when it comes to cryptocurrencies.

Between the lines: The SEC in December sued Ripple, and Garlinghouse personally, for allegedly selling over $1.3 billion in unregistered securities. Ripple's response is that its cryptocurrency, called XRP, didn't require registration because it's an asset rather than a security.

Caitlin Owens, author of Vitals
4 hours ago - Health

Pfizer CEO: "It will be terrible" if COVID-19 vaccine prices limit access

Pfizer CEO Albert Bourla told "Axios on HBO" that it "will be terrible for society" if the price of coronavirus vaccines ever prohibits some people from taking them.

Why it matters: Widespread uptake of the vaccine — which might require annual booster shots — will reduce the risk of the virus continuing to spread and mutate, but it's unclear who will pay for future shots or how much they'll cost.